Inhibikase Therapeutics progresses in Parkinson’s disease trials By Investing.com
BOSTON and ATLANTA - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company engaged in developing treatments for Parkinson's disease and related disorders, has announced significant advancements in its clinical trials,…